365
Participants
Start Date
July 31, 2015
Primary Completion Date
March 31, 2018
Study Completion Date
February 28, 2021
Chidamide
30 mg, administered orally twice per week (BIW)
exemestane
25 mg, PO daily
placebo
Administered orally twice per week (BIW)
The 307th Hospital of Chinese people's Liberation Army, Beijing
Beijing Cancer Hospital, Beijing
Liaoning Cancer Hospital & Institute, Shenyang
Jilin Cancer Hospital, Changchun
The First Hospital of Jilin University, Changchun
Harbin Medical University Cancer Hospital, Harbin
Fudan University Shanghai Cancer Center, Shanghai
Fudan University ZhongShan Hospital, Shanghai
Jiangsu Cancer Hospital, Nanjing
Jiangsu Province Hospital, Nanjing
Anhui Provincial Hospital, Hefei
The First Affiliated Hospital of Anhui Medical University, Hefei
Jinan Central Hospital, Jinan
Tianjin Medical University Cancer Institute and Hospital, Tianjin
Zhejiang Cancer Hospital, Hangzhou
The Third Hospital of Nanchang, Nanchang
Henan Cancer Hospital, Zhengzhou
Sun Yat-sen University Cancer Center, Guangzhou
Peking University Shenzhen Hospital, Shenzhen
Cangzhou Central Hospital, Cangzhou
Tumor Hospital of Hebei Province, Shijiazhuang
Hunan Cancer Hospital, Changsha
Lead Sponsor
Chipscreen Biosciences, Ltd.
INDUSTRY